Recurrent ovarian carcinoma: diagnosis and second-line therapy.

Approximately 10% of patients with ovarian cancer will develop a recurrence. Successful treatment of recurring disease has been documented, and recent developments in chemotherapy are encouraging. In our study, CA125 Tumour Marker was a useful marker to monitor the course of such disease, and detected recurring ovarian cancer at a sub-clinical level, leading to earlier diagnosis. This may have implications for outcome.